Onkos Surgical Ribbon Slicing (Featured left to proper): Erin D’Auria, John Coelho, Gene Kulesha, Dr. Steven Gitelis, Michael Kirsh, Patrick Treacy, and Althea Ford.
Modern know-how helps surgeons mitigate dangers of bacterial contamination on orthopaedic implant surfaces in working rooms
Addition of a brand new 4,600-square-foot manufacturing facility in Bridgewater, New Jersey, to its headquarters in Parsippany strengthens Onkos Surgical’s dedication to the area
PARSIPPANY, N.J., Dec. 10, 2025 /PRNewswire/ — Onkos Surgical, a number one supplier of progressive options for advanced orthopaedic procedures, has opened the NanoCept Innovation Heart, a brand new facility in Bridgewater Township, NJ.
Positioned within the New Jersey Heart of Excellence Campus, the brand new 4,600-square-foot facility will permit the corporate to convey a full innovation course of in-house for its flagship NanoCept® Antibacterial Know-how, the primary ever orthopaedic antibacterial coating commercially out there on the U.S. market. The product provides a proactive strategy in opposition to intraoperative bacterial contamination, a vital development within the discipline of orthopaedic implants. The manufacturing capability enlargement will permit the corporate to satisfy a rising demand for the NanoCept know-how from surgeons and hospitals.
“Onkos is proud to have labored with the FDA to convey to market the primary antibacterial coating know-how. The opening of the NanoCept Innovation Heart marks one other necessary milestone in our firm’s journey,” stated Patrick Treacy, Founder and CEO. “This funding will permit us to get this groundbreaking know-how into the fingers of extra surgeons, sooner, and it places us able to assist extra sufferers with advanced orthopaedic circumstances.”
“I’m excited by Onkos’ dedication to convey this know-how to extra implants and in the end to extra sufferers,” stated Steven Gitelis, MD, Director of Rush College/MD Anderson’s Orthopaedic Oncology Program and Chief Medical Officer of Onkos. “It is a distinctive know-how that arms us, as surgeons, with a robust answer to assist mitigate the intense situation of micro organism within the working room.”
Onkos Surgical’s dedication to the New Jersey area
Opening the brand new facility in Bridgewater underscores Onkos Surgical’s sturdy dedication to the area. The NanoCept Innovation Heart will make use of a group of chemists, engineers, and technicians within the new facility to guide its innovation operations. The corporate’s headquarters are positioned at 77 East Halsey Highway in Parsippany, NJ.
“The opening of the NanoCept Innovation Heart in Bridgewater exemplifies the cutting-edge innovation that defines New Jersey’s seventh Congressional District,” stated Congressman Tom Kean, Jr. “Developments like these being pursued by Onkos Surgical have the potential to drive significant progress in affected person care and develop prospects in trendy drugs. Congratulations to Onkos on this outstanding milestone.”
Onkos Surgical held a ribbon slicing ceremony to have a good time the opening of the NanoCept Innovation Heart on December 9, 2025. Amongst friends had been Steven Gitelis, MD, Director of Rush College/MD Anderson’s Orthopaedic Oncology Program and Chief Medical Officer of Onkos; Michael Kirsh, Township Councilman, Township of Bridgewater; Althea D. Ford, Vice President, Authorities Affairs, New Jersey Enterprise & Business Affiliation; Erin D’Auria, District Director for Congressman Tom Keane Jr. representing the 7th District of New Jersey; John Coelho, Life Sciences Strategic Innovation Senior Advisor at New Jersey Financial Improvement Authority (NJEDA); and Jessica Paolini, Director, Financial Improvement for Somerset County, Workplace of the County Administrator.
About Onkos Surgical
Onkos Surgical is a frontrunner in progressive options for advanced orthopaedic circumstances. With our novel product portfolio, surgeons are higher knowledgeable about patient-specific scientific challenges and are in a position to plan and implement extra exact reconstructions. Our personalised strategy helps improved affected person outcomes and experiences utilizing the most recent improvements in antibacterial implant coatings, digital surgical planning, 3D anatomic modeling and printing, implant design, and workflow optimization. Greater than 350 of the main tutorial medical establishments within the US select Onkos for his or her advanced revision and tumor orthopaedic instances. The NanoCept know-how is designed to guard orthopaedic implants throughout surgical procedure, previous to implantation. The NanoCept know-how’s effectiveness has not been proven in human scientific trials to stop or cut back an infection charges. For extra info on Onkos Surgical and its services and products, please go to www.onkossurgical.com/nanocept.
Ahead Trying Statements:
Sure statements made on this launch that aren’t statements of historic or present details are forward-looking statements which contain identified and unknown dangers, uncertainties and different elements that will trigger the precise outcomes, efficiency, or achievements of the corporate to be materially completely different from historic outcomes or from any future outcomes or projections expressed or implied by such forward-looking statements. In lots of instances, forward-looking statements might be recognized by phrases reminiscent of “future,” “believes,” “expects,” “could,” “will,” “ought to,” “potential,” “estimates,” “intends,” “anticipates” or “plans” or the detrimental of those phrases or different comparable terminology. Ahead-looking statements are primarily based upon administration’s beliefs, assumptions and present expectations however are topic to identified and unknown dangers and uncertainties together with, with out limitation, the likelihood that post-market scientific outcomes could also be inconsistent with the in-vitro preclinical check outcomes and the potential for brand new applied sciences and procedures to disrupt market demand. Though administration believes that the expectations mirrored within the forward-looking statements are affordable, forward-looking statements should not, and shouldn’t be relied upon as a assure of future efficiency or outcomes. The forward-looking statements included are made solely on the date of this launch. The corporate assumes no obligation to replace any info or forward-looking assertion contained herein, save for any info required to be disclosed by legislation.
Media Contact:
Alyssa Paldo
Vice-President, Media Relations Specialist
FINN Companions
alyssa.paldo@finnpartners.com
847.791.8085
SOURCE ONKOS SURGICAL
Leave a Reply